abstract |
Use of a compound of formula (I) :( in which RC and RD taken together with the neighboring carbon atoms form a 5 to 6 membered ring that may contain a heteroatom (s) of N and / or O and it may be condensed with a benzene ring; Y is hydroxyl; Z is O; RA is a group shown by (in which ring C is an aromatic heterocycle containing 5 to 6 membered N which may contain 1 to 4 atoms ( s) of O, S and / or N, in which at least one atom adjacent to the atom in the junction position is an atom of unsubstituted N; the dashed line shows the presence or absence of a bond) or by (in the that, X is O; RB is amino); at least one of the ring formed by RC and RD, ring C and RB is substituted with a group of -Z1-Z2-Z3-R1 (where Z1 and Z3 are each one independently a bond, alkylene or alkenylene; Z2 is a bond, alkylene, alkenylene, -CH (OH) -, - S-, -SO-, -SO2-, -SO2NR2-, -NR2SO2-, -O-, - NR2-, -NR2CO-, -CONR2-, -C (> = O) -O-, -OC (> = O) or -CO-; R2 is hydrogen, at chyl, alkenyl, aryl or heteroaryl; R1 is cycloalkyl, aryl or heteroaryl, R1 being optionally substituted with one or two substituents selected from C1-C6 alkyl, C1-C6 haloalkyl, halogen or C1-C6 alkoxy; the ring formed by RC and RD is optionally substituted with a substituent that does not inter-selected from hydrogen, halogen, C1-C6 alkyl, C3-C6 cycloalkyl, phenyl or naphthyl, C1-C6 alkoxy, C1-C6 alkoxy-C1-C6 alkyl, amino, C1-C6 hydroxyalkyl, C2-C8 alkenyl or hydroxyl , and the C or RB ring is optionally substituted with a non-interfering substituent selected from hydrogen, C1-C6 alkyl, amino, halogen and hydroxyl, at any position other than that in which the group of Z1-Z2-Z3- is located. R1 (wherein Z1, Z2, Z3 and R1 are the same as defined above); or a solvate or a pharmaceutically acceptable salt thereof, for the preparation of a pharmaceutical composition to prevent or treat a viral disease. |